US20150343113A1 - Polymeric sealant for use in mammals (as amended) - Google Patents
Polymeric sealant for use in mammals (as amended) Download PDFInfo
- Publication number
- US20150343113A1 US20150343113A1 US14/822,568 US201514822568A US2015343113A1 US 20150343113 A1 US20150343113 A1 US 20150343113A1 US 201514822568 A US201514822568 A US 201514822568A US 2015343113 A1 US2015343113 A1 US 2015343113A1
- Authority
- US
- United States
- Prior art keywords
- sealant
- polymeric film
- forming medical
- sealant according
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J133/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
- C09J133/04—Homopolymers or copolymers of esters
- C09J133/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur or oxygen atoms in addition to the carboxy oxygen
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J139/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Adhesives based on derivatives of such polymers
- C09J139/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C09J139/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J167/00—Adhesives based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Adhesives based on derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J167/00—Adhesives based on polyesters obtained by reactions forming a carboxylic ester link in the main chain; Adhesives based on derivatives of such polymers
- C09J167/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J169/00—Adhesives based on polycarbonates; Adhesives based on derivatives of polycarbonates
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J175/00—Adhesives based on polyureas or polyurethanes; Adhesives based on derivatives of such polymers
- C09J175/04—Polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J177/00—Adhesives based on polyamides obtained by reactions forming a carboxylic amide link in the main chain; Adhesives based on derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J179/00—Adhesives based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen, with or without oxygen, or carbon only, not provided for in groups C09J161/00 - C09J177/00
- C09J179/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J185/00—Adhesives based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon; Adhesives based on derivatives of such polymers
- C09J185/02—Adhesives based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon; Adhesives based on derivatives of such polymers containing phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates generally to the field of film-forming medical compositions, more specifically to methods and products used to seal mucosa, lessen pain and facilitate recovery by application of a polymeric sealant composition for use in bodily tissues, such as treatment of the throat, tonsils and/or adenoids.
- Adenoids pharyngeal tonsils and tonsils (palatine tonsils) are involved in a number of diseases of the ear, nose, and throat including chronic otitis media with effusion (COME), recurrent acute otitis media (RAOM), adenoiditis, pediatric chronic sinusitis, tonsillitis, pediatric obstructive sleep apnea (OSA), adult OSA, and chronic strep throat. Lingual tonsils can also become infected and be problematic. Treatment for these diseases is primarily achieved first by use of oral medications or, in the case of pediatric and adult sleep apnea through the use of continuous positive airway pressure (CPAP). Otitis media is most often treated primarily with ventilation tube surgery.
- CPAP continuous positive airway pressure
- a polymeric film-forming medical sealant composition may be applied to the throat to provide multiple treatment and/or prophylactic functions such as reduction of bleeding, prevention of post-operative infections, tissue protection, reduction in pain, and the like. It is also anticipated that such sealant could be used in the throat, especially on the tonsils, adenoids or the post-operative adenoid remnant to treat otitis media, given the involvement in the disease.
- Useful polymeric film-forming medical sealants of the invention may be applied directly to the affected area, are generally resorbable materials which may have residence times of one day or many days or weeks.
- the invention provides a polymeric film-forming sealant for use in medical applications.
- the invention provides a polymeric film-forming sealant which is useful in applications for treatment and/or post-operative care of the tonsils and adenoids.
- the invention provides a polymeric film-forming medical sealant useful for application to the tonsils and adenoids, wherein the sealant performs at least one of the following functions, a) inhibits the colonization of bacteria, b) inhibits the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, especially postoperative healing, and f) delivery of therapeutic agent(s).
- the application of the polymeric sealant of the invention also reduces pain in tissue to which it is applied during treatment or postoperative healing.
- the application of the polymeric sealant of the invention also reduces bleeding in tissue to which it is applied.
- the polymeric film-forming medical sealant of the invention may further be comprised of a natural therapeutic material such as chitosan, etc. or include at least one therapeutic agent.
- the sealant further includes a therapeutic agent selected from the group consisting of analgesics, antihistamines, anti-infective agents, anti-bacteria adhesion agents, anti-fungal agents, biostatic compositions, anti-inflammatory agents, anti-cholinergics, anti-neoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, immunosuppressors, vasoconstrictors, and mixtures thereof.
- the polymeric sealant of the invention may be a viscoelastic material.
- the polymeric sealant of the invention may harden after application.
- the sealant is a resorbable material having a residence time in vivo of from one day to weeks or months.
- the invention also provides a method of treatment for maladies or chronic conditions of the tonsils or adenoids which comprises the step of providing at least one polymeric film-forming medical sealant, and applying it to the tonsils, adenoids or adjacent tissue.
- the invention further provides a method of postoperative treatment for use after removal of the tonsils or adenoids which comprises the step of providing least one polymeric film-forming medical sealant, and applying it to the throat, such as to tonsillar fossa.
- bioresorbable means capable of being absorbed by the body.
- thermometer means a device or material which stops blood flow.
- adheresion refers to the sticking together of a material to tissues with which it is in intimate contact for extended periods.
- the term “residence time” means the time which the sealant remains in place in vivo.
- polymeric sealant means that the sealant is either formed from a synthetic polymer or is a natural polymeric material such as a protein, which is crosslinked.
- biodegradable means that the substance will degrade or erode in vivo to form smaller chemical species. Such degradation process may be enzymatic, chemical or physical.
- biocompatible means that the substance presents no significant deleterious or untoward effects upon the body.
- the polymeric medical sealant provided herein may be used in any manner in which will promote therapeutic improvement. Such uses include, but are not limited to wound management, tissue protection, reduction or elimination of bleeding, reduction of pain, promotion of healing, prevention of infection, and the like.
- the sealants may also be used as single or combination drug delivery systems for humans or mammals.
- the sealant of the invention is a biocompatible composition which adheres to bodily tissues. Most useful sealants are resorbable or degradable, as a non-resorbable or non-degradable adhesive or sealant cannot be used where damaged tissues are not meant to grow together as a permanent or semi-permanent barrier is created if the sealant is not resorbed or degraded.
- the sealant may be a polymeric polymer such as silk or silk-elastin polymers which are crosslinked just prior to delivery which can then be sprayed onto the tissue.
- Useful biodegradable polymers arid oligomers include, but are not limited to: poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), polycaprolactones, polyamides, poly(malic acids), polyanhydrides, polyamino acids, polyorthoesters, polyetheresters, polycyanoacrylates, polyphosphazines, polyphosphoesters, polyesteramides, polydiozanones, polyacetals, polyketals, polycarbonates, degradable polyurethanes, polyvinyl pyrrolidones, polyhydroxybutyrates, polyhydoxyvalerates, polyalkylene oxalates, polyalkylene succinates, chitins, chitosans
- Useful crosslinking materials include, but are not limited to, polyethylene glycol (PEG), chitin, carboxymethylcellulose, and the like, carbodiimides, diisocyanates and/or aldehydes; such as glutaraldehyde or formaldehyde.
- PEG polyethylene glycol
- chitin carboxymethylcellulose
- carbodiimides diisocyanates
- aldehydes such as glutaraldehyde or formaldehyde.
- the material cures to form a hydrogel, which strongly adheres to the tissue.
- the sealant may be a natural protein such as collagen or albumin which is crosslinked, most typically with aldehydes, such as glutaraldehyde or formaldehyde.
- the sealant may include a glycol along with a natural protein such as chitin, collagen, agar or albumin.
- the glycol may be a material such as a polyethylene glycol.
- the sealant of the invention may be applied in any known form, such as a gel, one or more flowable liquids that crosslink, polymerize or otherwise alter their consistency to form a sealant, a film strip or sheet material, as a sponge, or as a powder which forms into a sealant or in atomized form may be sprayed onto the tissue.
- a gel such as a gel, one or more flowable liquids that crosslink, polymerize or otherwise alter their consistency to form a sealant, a film strip or sheet material, as a sponge, or as a powder which forms into a sealant or in atomized form may be sprayed onto the tissue.
- the polymeric film-forming medical sealants useful for application to the tonsils and adenoids perform at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, f) promotion of healing, and g) reduction of pain.
- they may also reduce the formation of post-operative peri-tonsillar abscess formation by reduction of infection and biofilm formation due to the protection of the tissues, and/or inclusion of anti-infective agents.
- the polymeric film-forming medical sealant may be comprised of a natural therapeutic biomaterial or may include one or more therapeutic agents.
- the therapeutic agent that may be added to the sealant is not limited in nature, and any agent which is appropriate for medical use may be used.
- Some common therapeutic agents are those selected from the group consisting of analgesics, antihistamines, anti-infective agents such as anti-bacterial and anti-fungal agents, biostatic compositions, anti-inflammatory agents, anti-cholinergics, anti-neoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, vasoconstrictors and mixtures thereof.
- useful additional therapeutic agents include but are not limited to those listed herein.
- Some useful antibacterial agents include aminoglycosides, amphenicols, ansamycins, beta-lactams such as penicillins, ampicillins, cephalosporins, lincosamides, macrolides, nitrofurans, quinolines, sulfonamides, sulfones, tetracycline antibiotics such as chlortricycline, oxytetracycline, demecocycline, doxycycline, democycline, minocycline, methocycline, mecoclycline, methacycline, lymecycline, and the like, vancomycin, and derivatives thereof and mixtures thereof.
- Examples of anti-fungals include allylamines, imidazoles, polyenes, thiocarbamates, triazoles, and derivatives thereof.
- Anti-parasitic agents include atovaquone, clindamycin and the like.
- the tetracycline family of materials is preferred therapeutic agents for their combination of anti-inflammatory properties and anti-infective properties.
- ⁇ -lactams that may be suitable for use with the described methods and devices include, but are not limited to, carbacephems, carbapenems, cephalosporins, cephamycins, monobactams, oxacephems, penicillins, and any of their derivatives.
- Penicillins that may be suitable for use include, but are not limited to, amdinocillin, amdinocillin pivoxil, amoxicillin ampicillin, apalcillin, aspoxicillin, axidocillin, azlocillin, acampicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, carbenicillin, carindacillin, clometocillin, cloxacillin, cyclacillin, dicloxacillin, epicillin, fenbenicillin, floxacillin, hetacillin, lenampicillin, metampicillin, methicillin sodium, mezlocillin, nafcillin sodium, oxacillin, penamecillin, penethamate hydriodide, penicillin G benethamine, penicillin G benzathine, penicillin G benzhydrylamine, penicillin G calcium, penicillin G hydrabamine, penicillin G potassium
- procaine penicillin N, penicillin O, penicillin V, penicillin V banzathine, penicillin V hydrabamine, penimepicycline, phenethicillin potassium, piperacillin, pivampicillin propicillin, quinacillin, sulbenicillin, sultamicillin, talampicillin, temocillin, and ticarcillin.
- amoxicillin may be included in the paranasal sinus device.
- the additional agent includes ampicillin. Penicillins combined with clavulanic aid such as Augmentin® (amoxicillin and clavulanic acid) may also be used.
- antifungal agents suitable for use include, but are not limited to, allylamines, imidazoles, polyenes, thiocarbamates, triazoles, and any of their derivatives.
- imidazoles are the preferred antifungal agents.
- Anti-parasitic agents that may be employed include such agents as atovaquone clindamycin, dapsone, iodoquinol, metronidazle, pentamidine, primaquine, pyrimethamine, sulfadiazine, trimethoprim/sufamethoxazole, trimetrexate, and combinations thereof.
- antiviral agents suitable for use include, but are not limited to acyclovir, famciclovir, valacyclovir, edoxudine, ganciclovir, foscamet, cidovir (vistide), vitrasert, formivirsen, HPMPA (9-(3-hydroxy-2-phosphonomethoxypropyl)adenine), PMEA (9-(2-phosphonomethoxyethyl)adenine), HPMPG (9-(3-Hydroxy-2-(Phosphonomethoxy)propyl)guanine), PMEG (9-[2-(phosphonomethoxy)ethyl]guanine), HPMPC (1-(2- phosphonomethoxy-3-hydroxypropyl)-cytosine), ribavirin, EICAR (5-ethynl-1-beta-D-ribofuranosylimidazole-4-carbonxamine), pyrazofurin (3-[beta-D-ribof
- steroidal anti-inflammatory agents examples include 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetansone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone
- budesonide is included in the device as the steroidal anti-inflammatory agent.
- the steroidal anti-inflammatory agent may be mometasonefuroate.
- the steroidal anti-inflammatory agent may be beclomethasone.
- the steroidal anti-inflammatory agent may be fluticasone propionate.
- Suitable nonsteroidal anti-inflammatory agents include, but are not limited to, COX inhibitors (COX-1 or COX nonspecific inhibitors) (e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salicylate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam
- chemotherapeutic/antineoplastic agents that may be used include, but are not limited to antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers vascularization inhibitors, hormone receptor blocks, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis) such as alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide) nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNU) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6 mercaptopurine and 5-fluorouracil (5FU)), antitumor antibiotics and other compounds that act by binding or intercalating DNA and preventing RNA synthesis (e.g., doxorubicin, da
- biological response modifiers e.g., interferon, bacillus calmette-guerin (BCG), monoclonal antibodies, interleuken 2, granulocyte colony stimulating factor (GCSF), etc.
- PGDF receptor antagonists herceptin, asparaginase, busulphan, carboplatin, cisplatin, carmustine, chlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, flurouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxaliplatin, procarbamate, asparaginase, busulphan, carboplatin, cisplatin, carmus
- Exemplary decongestants include, but are not limited to, epinephrine, pseudoephedrine, oxymetazoline, phenylephrine, tetrahydrozolidine, and xylometazoline.
- Mucolytics that may be used include, but are not limited to, acetylcysteine, dornase alpha, and guaifenesin.
- Antihistamines such as azelastine, diphenhydramine, and loratidine may also be used.
- a hyperosmolar agent may be employed.
- Suitable hyperosmolar agents include, but are not limited to, furosemide, sodium chloride gel, or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous layer.
- a release agent modifier or other hydrophilic and/or hydrophobic material such as hydroxypropylcellulose, poly(ethylene oxide), polylactic acid hydroxypropyl methylcellulose, ethylcellulose, cellulosic polymers, acrylic polymers, fats, waxes, lipids, polysaccharides, and mixtures thereof may also be present in the medical sealant.
- the therapeutic agent may also be contained within polymeric microspheres to further delay and/or sustain release of the agent.
- the medical sealant may also, if desired include such additives and flavorant where appropriate. Any known flavorant may be used. Examples include anise oil, cinnamon oil, cocoa, menthol, orange or other citrus oils, peppermint oil, spearmint oil, vanillin, fruit flavors and essences, herbal aromatics such as clove oil, sage oil, cassia oil, and the like.
- the sealant may also include a colorant such as FD & C Red No. 3, FD & C Red No. 20, FD & C Yellow No. 6, FD & C Blue No. 2, D & C Green No. 5, D & C Orange N. 4, D & C Red No. 8, caramel, titanium dioxide, fruit or vegetable colorants such as beet powder, or beta-carotene, turmeric, paprika and others known in the art. The colorant is included to provide visual notification of the presence of the sealant.
Abstract
The invention provides a polymeric medical sealant for use in mammals other than humans. The medical sealant is useful for application to the tonsils, adenoids or paranasal sinus, wherein the sealant performs at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, f) promotion of healing, and g) reduction of pain.
Description
- This application is a Divisional of U.S. application Ser. No. 11/704,115, filed Feb. 8, 2007, the disclosure of which is incorporated herein by reference.
- The present invention relates generally to the field of film-forming medical compositions, more specifically to methods and products used to seal mucosa, lessen pain and facilitate recovery by application of a polymeric sealant composition for use in bodily tissues, such as treatment of the throat, tonsils and/or adenoids.
- Adenoids (pharyngeal tonsils) and tonsils (palatine tonsils) are involved in a number of diseases of the ear, nose, and throat including chronic otitis media with effusion (COME), recurrent acute otitis media (RAOM), adenoiditis, pediatric chronic sinusitis, tonsillitis, pediatric obstructive sleep apnea (OSA), adult OSA, and chronic strep throat. Lingual tonsils can also become infected and be problematic. Treatment for these diseases is primarily achieved first by use of oral medications or, in the case of pediatric and adult sleep apnea through the use of continuous positive airway pressure (CPAP). Otitis media is most often treated primarily with ventilation tube surgery. Failure of these therapies is often followed by surgical removal of the tonsils and/or adenoids to remove them either because they are a harbor for bacteria or as obstructing anatomy. Complications related to these procedures include post-operative bleeding, dehydration, weight loss, peritonsillar abscess, torticilis (neck stiffness), regrowth of tissue, redo surgery due to incomplete removal of tissue, continued COME or RAOM, continued OSA, and occasionally death. Post-operative treatment has traditionally been limited to dietary limitation, rinses, and use of oral antibiotics to prevent post-operative pain and infections.
- It has now been discovered that a polymeric film-forming medical sealant composition may be applied to the throat to provide multiple treatment and/or prophylactic functions such as reduction of bleeding, prevention of post-operative infections, tissue protection, reduction in pain, and the like. It is also anticipated that such sealant could be used in the throat, especially on the tonsils, adenoids or the post-operative adenoid remnant to treat otitis media, given the involvement in the disease.
- Useful polymeric film-forming medical sealants of the invention may be applied directly to the affected area, are generally resorbable materials which may have residence times of one day or many days or weeks.
- The invention provides a polymeric film-forming sealant for use in medical applications.
- Specifically, the invention provides a polymeric film-forming sealant which is useful in applications for treatment and/or post-operative care of the tonsils and adenoids.
- More specifically, the invention provides a polymeric film-forming medical sealant useful for application to the tonsils and adenoids, wherein the sealant performs at least one of the following functions, a) inhibits the colonization of bacteria, b) inhibits the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, especially postoperative healing, and f) delivery of therapeutic agent(s). In one embodiment, the application of the polymeric sealant of the invention also reduces pain in tissue to which it is applied during treatment or postoperative healing. In another embodiment, the application of the polymeric sealant of the invention also reduces bleeding in tissue to which it is applied.
- The polymeric film-forming medical sealant of the invention may further be comprised of a natural therapeutic material such as chitosan, etc. or include at least one therapeutic agent. In one embodiment, the sealant further includes a therapeutic agent selected from the group consisting of analgesics, antihistamines, anti-infective agents, anti-bacteria adhesion agents, anti-fungal agents, biostatic compositions, anti-inflammatory agents, anti-cholinergics, anti-neoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, immunosuppressors, vasoconstrictors, and mixtures thereof.
- The polymeric sealant of the invention may be a viscoelastic material. In another embodiment, the polymeric sealant of the invention may harden after application. In most embodiments, the sealant is a resorbable material having a residence time in vivo of from one day to weeks or months.
- The invention also provides a method of treatment for maladies or chronic conditions of the tonsils or adenoids which comprises the step of providing at least one polymeric film-forming medical sealant, and applying it to the tonsils, adenoids or adjacent tissue. The invention further provides a method of postoperative treatment for use after removal of the tonsils or adenoids which comprises the step of providing least one polymeric film-forming medical sealant, and applying it to the throat, such as to tonsillar fossa.
- These terms when used herein have the following meanings:
- 1. The term “bioresorbable” as used herein, means capable of being absorbed by the body.
- 2. The term “hemostat” means a device or material which stops blood flow.
- 3. The term “adhesion” as used herein, refers to the sticking together of a material to tissues with which it is in intimate contact for extended periods.
- 4. The term “residence time” means the time which the sealant remains in place in vivo.
- 5. The term “polymeric sealant” means that the sealant is either formed from a synthetic polymer or is a natural polymeric material such as a protein, which is crosslinked.
- 6. The term “biodegradable” means that the substance will degrade or erode in vivo to form smaller chemical species. Such degradation process may be enzymatic, chemical or physical.
- 7. The term “biocompatible” means that the substance presents no significant deleterious or untoward effects upon the body.
- The following detailed description describes certain embodiments and is not to be taken in a limiting sense. The scope of the present invention is defined by the appended claims.
- The polymeric medical sealant provided herein may be used in any manner in which will promote therapeutic improvement. Such uses include, but are not limited to wound management, tissue protection, reduction or elimination of bleeding, reduction of pain, promotion of healing, prevention of infection, and the like. The sealants may also be used as single or combination drug delivery systems for humans or mammals.
- The sealant of the invention is a biocompatible composition which adheres to bodily tissues. Most useful sealants are resorbable or degradable, as a non-resorbable or non-degradable adhesive or sealant cannot be used where damaged tissues are not meant to grow together as a permanent or semi-permanent barrier is created if the sealant is not resorbed or degraded.
- In one embodiment the sealant may be a polymeric polymer such as silk or silk-elastin polymers which are crosslinked just prior to delivery which can then be sprayed onto the tissue. Useful biodegradable polymers arid oligomers include, but are not limited to: poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acids), poly(glycolic acids), polycaprolactones, polyamides, poly(malic acids), polyanhydrides, polyamino acids, polyorthoesters, polyetheresters, polycyanoacrylates, polyphosphazines, polyphosphoesters, polyesteramides, polydiozanones, polyacetals, polyketals, polycarbonates, degradable polyurethanes, polyvinyl pyrrolidones, polyhydroxybutyrates, polyhydoxyvalerates, polyalkylene oxalates, polyalkylene succinates, chitins, chitosans, oxidized celluloses, carboxymethylcellulose, gelatin, agar, and copolymers, terpolymers, blends, and mixtures thereof.
- Useful crosslinking materials include, but are not limited to, polyethylene glycol (PEG), chitin, carboxymethylcellulose, and the like, carbodiimides, diisocyanates and/or aldehydes; such as glutaraldehyde or formaldehyde. The material cures to form a hydrogel, which strongly adheres to the tissue.
- In another embodiment, the sealant may be a natural protein such as collagen or albumin which is crosslinked, most typically with aldehydes, such as glutaraldehyde or formaldehyde.
- In yet another embodiment, the sealant may include a glycol along with a natural protein such as chitin, collagen, agar or albumin. The glycol may be a material such as a polyethylene glycol.
- The sealant of the invention may be applied in any known form, such as a gel, one or more flowable liquids that crosslink, polymerize or otherwise alter their consistency to form a sealant, a film strip or sheet material, as a sponge, or as a powder which forms into a sealant or in atomized form may be sprayed onto the tissue.
- The polymeric film-forming medical sealants useful for application to the tonsils and adenoids perform at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, f) promotion of healing, and g) reduction of pain. In surgical applications, they may also reduce the formation of post-operative peri-tonsillar abscess formation by reduction of infection and biofilm formation due to the protection of the tissues, and/or inclusion of anti-infective agents. Healing is promoted through wound closure, and maintenance of the wound as a moist wound, which promotes platelet aggregation, and wound closure without excessive scabrous formations, which occur in drier wounds. Acceleration of wound healing and protection of the wound also reduce the chances of infection at the wound site, and resultant pain, inflammation and malodor.
- The polymeric film-forming medical sealant may be comprised of a natural therapeutic biomaterial or may include one or more therapeutic agents. The therapeutic agent that may be added to the sealant is not limited in nature, and any agent which is appropriate for medical use may be used. Some common therapeutic agents are those selected from the group consisting of analgesics, antihistamines, anti-infective agents such as anti-bacterial and anti-fungal agents, biostatic compositions, anti-inflammatory agents, anti-cholinergics, anti-neoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, vasoconstrictors and mixtures thereof.
- Examples of useful additional therapeutic agents include but are not limited to those listed herein. Some useful antibacterial agents include aminoglycosides, amphenicols, ansamycins, beta-lactams such as penicillins, ampicillins, cephalosporins, lincosamides, macrolides, nitrofurans, quinolines, sulfonamides, sulfones, tetracycline antibiotics such as chlortricycline, oxytetracycline, demecocycline, doxycycline, democycline, minocycline, methocycline, mecoclycline, methacycline, lymecycline, and the like, vancomycin, and derivatives thereof and mixtures thereof. Examples of anti-fungals include allylamines, imidazoles, polyenes, thiocarbamates, triazoles, and derivatives thereof. Anti-parasitic agents include atovaquone, clindamycin and the like.
- In one embodiment, the tetracycline family of materials is preferred therapeutic agents for their combination of anti-inflammatory properties and anti-infective properties. β-lactams that may be suitable for use with the described methods and devices include, but are not limited to, carbacephems, carbapenems, cephalosporins, cephamycins, monobactams, oxacephems, penicillins, and any of their derivatives. Penicillins that may be suitable for use include, but are not limited to, amdinocillin, amdinocillin pivoxil, amoxicillin ampicillin, apalcillin, aspoxicillin, axidocillin, azlocillin, acampicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, carbenicillin, carindacillin, clometocillin, cloxacillin, cyclacillin, dicloxacillin, epicillin, fenbenicillin, floxacillin, hetacillin, lenampicillin, metampicillin, methicillin sodium, mezlocillin, nafcillin sodium, oxacillin, penamecillin, penethamate hydriodide, penicillin G benethamine, penicillin G benzathine, penicillin G benzhydrylamine, penicillin G calcium, penicillin G hydrabamine, penicillin G potassium, penicillin G. procaine, penicillin N, penicillin O, penicillin V, penicillin V banzathine, penicillin V hydrabamine, penimepicycline, phenethicillin potassium, piperacillin, pivampicillin propicillin, quinacillin, sulbenicillin, sultamicillin, talampicillin, temocillin, and ticarcillin. In one variation, amoxicillin may be included in the paranasal sinus device. In another variation, the additional agent includes ampicillin. Penicillins combined with clavulanic aid such as Augmentin® (amoxicillin and clavulanic acid) may also be used.
- Examples of antifungal agents suitable for use include, but are not limited to, allylamines, imidazoles, polyenes, thiocarbamates, triazoles, and any of their derivatives. In one variation, imidazoles are the preferred antifungal agents. Anti-parasitic agents that may be employed include such agents as atovaquone clindamycin, dapsone, iodoquinol, metronidazle, pentamidine, primaquine, pyrimethamine, sulfadiazine, trimethoprim/sufamethoxazole, trimetrexate, and combinations thereof.
- Examples of antiviral agents suitable for use include, but are not limited to acyclovir, famciclovir, valacyclovir, edoxudine, ganciclovir, foscamet, cidovir (vistide), vitrasert, formivirsen, HPMPA (9-(3-hydroxy-2-phosphonomethoxypropyl)adenine), PMEA (9-(2-phosphonomethoxyethyl)adenine), HPMPG (9-(3-Hydroxy-2-(Phosphonomethoxy)propyl)guanine), PMEG (9-[2-(phosphonomethoxy)ethyl]guanine), HPMPC (1-(2- phosphonomethoxy-3-hydroxypropyl)-cytosine), ribavirin, EICAR (5-ethynl-1-beta-D-ribofuranosylimidazole-4-carbonxamine), pyrazofurin (3-[beta-D-ribofuranosyl]-4-hydroxypyrazole-5-carboxamine), 3-Deazaguanine, GR-92938X (1-beta-D-ribofuranosylpyrazole-3,4-dicarboxamide), LY253963 (1,34-thiadiazol-2-yl-cyanamide), RD3-0028 (1,4-dihydro-2,3-Benzodithiin), CL387626 (4,4′-bis[4,6-d][3-aminophenyl-N-N-bis(2-carbamoylethyl)-sulfonilimino]-1,3,5-triazin-2-ylamino-biphenyl-2-,2′-disulfonic acid disodium salt), BABIM (Bis[5-Amidino-2-benzimidazoly-1]-methane), NIH351, and combinations thereof.
- Examples of steroidal anti-inflammatory agents that may be used in the devices include 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetansone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, halopredone acetate, hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone, mometasone furoate, paramethosone, prednicarbate, prednisolone, prednisolone 25-diethylamino-acetate, prednisolone sodium phosphate, prednisone, prednival, prednylidene, rimexolone, tixocortol, triamcinolone, triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, any of their derivatives, and combinations thereof. In one variation, budesonide is included in the device as the steroidal anti-inflammatory agent. In another variation the steroidal anti-inflammatory agent may be mometasonefuroate. In yet another variation, the steroidal anti-inflammatory agent may be beclomethasone. In yet a further variation, the steroidal anti-inflammatory agent may be fluticasone propionate.
- Suitable nonsteroidal anti-inflammatory agents include, but are not limited to, COX inhibitors (COX-1 or COX nonspecific inhibitors) (e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salicylate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam) and alkanones such as nabumetone) and selective COX-2 inhibitors (e.g., diaryl-substituted furanones such as refecoxib; diaryl-substituted pyrazoles such as celecoxib; indole acetic acids such as etodolac and sulfonanilides such as nimesulide).
- The chemotherapeutic/antineoplastic agents that may be used include, but are not limited to antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers vascularization inhibitors, hormone receptor blocks, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis) such as alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide) nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNU) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6 mercaptopurine and 5-fluorouracil (5FU)), antitumor antibiotics and other compounds that act by binding or intercalating DNA and preventing RNA synthesis (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitomycin-C and bleomycn) plant (vinca) alkaloids and other anti-tumor agents derived from plants (e.g, vincristine and vinblastine), steroid hormones, hormone inhibitors, hormone receptor antagonists and other agents which affect the growth of hormone-responsive cancers (e.g., tamoxifen, herceptin, aromatase inhibitors such as aminoglutethamide, and formestane, triazole inhibitors such as letrozole and anastrazole, steroidal inhibitors such as exemastane) antiangiogenic proteins, small molecules, gene therapies and/or other agents that inhibit angiogenesis or vascularization of tumors (e.g., meth-1, meth-2, thalidomide), bevacizumab (Avastin) squalamine, endostatin, angiostatin, Angiozyme, AE-941 (Neoastat), CC-5013 (Revimid), medi-522 (Vitaxin), 2-methoxyestradiol (2ME2, Panzem) carboxyamidotriazole (CAI) combretastatin A4 prodrug (CA4P), SU6668, SU11248, BMS-275291, COL-3, EMD 121974, IMC-1C11, IM862, TNP-470, celecoxib (Celebrex), refecoxib (Vioxx), interferon alpha, interleukin-12 (IL-12) or any of the compounds identified in Science Vol. 298, Pages 1197-1201 (Aug. 17, 2000), which is expressly incorporated herein by reference, biological response modifiers (e.g., interferon, bacillus calmette-guerin (BCG), monoclonal antibodies, interleuken 2, granulocyte colony stimulating factor (GCSF), etc.), PGDF receptor antagonists, herceptin, asparaginase, busulphan, carboplatin, cisplatin, carmustine, chlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, flurouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxaliplatin, procarbazine streptocin, taxol or paclitaxel, taxotere, analogs/congeners, derivatives of such compounds, and combinations thereof.
- Exemplary decongestants include, but are not limited to, epinephrine, pseudoephedrine, oxymetazoline, phenylephrine, tetrahydrozolidine, and xylometazoline. Mucolytics that may be used include, but are not limited to, acetylcysteine, dornase alpha, and guaifenesin. Antihistamines such as azelastine, diphenhydramine, and loratidine may also be used.
- In those instances where it is desirable to remove water from tissue, e.g., to remove fluid from polyps or edematous tissue, a hyperosmolar agent may be employed. Suitable hyperosmolar agents include, but are not limited to, furosemide, sodium chloride gel, or other salt preparations that draw water from tissue or substances that directly or indirectly change the osmolar content of the mucous layer.
- Where sustained release or delayed release of the therapeutic agent is desirable, a release agent modifier or other hydrophilic and/or hydrophobic material such as hydroxypropylcellulose, poly(ethylene oxide), polylactic acid hydroxypropyl methylcellulose, ethylcellulose, cellulosic polymers, acrylic polymers, fats, waxes, lipids, polysaccharides, and mixtures thereof may also be present in the medical sealant. The therapeutic agent may also be contained within polymeric microspheres to further delay and/or sustain release of the agent.
- The medical sealant may also, if desired include such additives and flavorant where appropriate. Any known flavorant may be used. Examples include anise oil, cinnamon oil, cocoa, menthol, orange or other citrus oils, peppermint oil, spearmint oil, vanillin, fruit flavors and essences, herbal aromatics such as clove oil, sage oil, cassia oil, and the like. The sealant may also include a colorant such as FD & C Red No. 3, FD & C Red No. 20, FD & C Yellow No. 6, FD & C Blue No. 2, D & C Green No. 5, D & C Orange N. 4, D & C Red No. 8, caramel, titanium dioxide, fruit or vegetable colorants such as beet powder, or beta-carotene, turmeric, paprika and others known in the art. The colorant is included to provide visual notification of the presence of the sealant.
- Although specific embodiments have been illustrated and described herein for purposes of description of the preferred embodiment, it will be appreciated by those of ordinary skill in the art that a wide variety of alternate and/or equivalent implementations calculated to achieve the same purposes may be substituted for the specific embodiments shown and described without departing from the scope of the present invention. Those with skill in the chemical, mechanical, biomedical; and biomaterials arts will readily appreciate that the present invention may be implemented in a very wide variety of embodiments. This application is intended to cover any adaptations or variations of the preferred embodiments discussed herein. Therefore, it is manifestly intended that this invention be limited only by the claims and the equivalents thereof.
Claims (27)
1: A polymeric film-forming medical sealant comprising a film, gel, sheet, sponge or powder applied to the tonsils, adenoids or paranasal sinus of a mammal other than a human, wherein the sealant performs at least one of the following functions, a) inhibiting the colonization of bacteria, b) inhibiting the binding of bacteria to tissue, c) reducing tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing, f) promoting healing, and g) reducing pain.
2: A polymeric film-forming medical sealant according to claim 1 wherein said sealant inhibits the colonization of bacteria.
3: A polymeric film-forming medical sealant according to claim 1 wherein said sealant inhibits the binding of bacteria to tissue.
4: A polymeric film-forming medical sealant according to claim 1 wherein said sealant reduces tissue morbidity in tissue to which it is applied.
5: A polymeric film-forming medical sealant according to claim 1 wherein said sealant reduces bleeding.
6: A polymeric film-forming medical sealant according to claim 1 wherein said sealant coats and protects tissue during healing.
7: A polymeric film-forming medical sealant according to claim 1 wherein the application of said sealant reduces pain in tissue to which it is applied during treatment or postoperative healing.
8. (canceled)
9: A polymeric film-forming medical sealant according to claim 1 wherein said sealant hardens or crosslinks to form a semi-pliable barrier upon application.
10: A polymeric film-forming medical sealant according to claim 1 wherein said sealant has a residence time of at least about one day.
11: A polymeric film-forming medical sealant according to claim 1 wherein said sealant has a residence time of at least about one week.
12: A polymeric film-forming medical sealant according to claim 1 wherein said sealant has a residence time of at least about one month.
13: A polymeric film-forming medical sealant according to claim 1 wherein said sealant is applied as an atomized powder or atomized liquid.
14. (canceled)
15: A polymeric film-forming medical sealant according to claim 8 wherein said sealant comprises a polyethylene glycol.
16: A polymeric film-forming medical sealant according to claim 1 wherein said sealant comprises a silk or silk-elastin polymer crosslinked with a crosslinking agent selected from an aldehyde, a thiol, or a chitosan.
17: A polymeric film-forming medical sealant according to claim 1 wherein said sealant is crosslinked with an aldehyde selected from formaldehyde and glutaraldehyde.
18: A polymeric film-forming medical sealant according to claim 1 further including at least one therapeutic agent selected from the group consisting of analgesics, antihistamines, anti-infective agents, anti-fungal agents, biostatic compositions, anti-inflammatory agents, anti-cholinergics, anti-neoplastic agents, cytokines, decongestants, vitamins, peptides, proteins, nucleic acids, immunosuppressors, vasoconstrictors and mixtures thereof.
19: A polymeric film-forming medical sealant according to claim 1 further including a blood product.
20: A method of treatment for conditions of the tonsils, adenoids or paranasal sinus of a mammal other than a human, which method comprises the step of providing at least one polymeric film-forming medical sealant according to claim 1 , and applying it to the tonsils, adenoids, paranasal sinus or adjacent tissue.
21-23. (canceled)
24: A polymeric film-forming medical sealant according to claim 1 wherein said sealant has a colorant that provides visual confirmation of the sealant present at a surgical site.
25: A polymeric film-forming medical sealant according to claim 1 wherein the sealant is a synthetic polymer.
26: A polymeric film-forming medical sealant according to claim 1 wherein the sealant is a natural polymer.
27: A polymeric film-forming medical sealant according to claim 1 wherein the sealant comprises a crosslinking material.
28: A polymeric film-forming medical sealant according to claim 1 wherein the sealant comprises a poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly(lactic acid), poly(glycolic acid), polycaprolactone, polyamide, poly(malic acid), polyanhydride, polyamino acid, polyorthoester, polyetherester, polycyanoacrylate, polyphosphazine, polyphosphoester, polyesteramide, polydiozanone, polyacetal, polyketal, polycarbonate, polyurethane, polyvinyl pyrrolidone, polyhydroxybutyrate, polyhydoxyvalerate, polyalkylene oxalate, polyalkylene succinate, or a copolymer, terpolymer, blend, or mixture thereof.
29: A polymeric film-forming medical sealant according to claim 1 wherein the sealant comprises hydroxypropylcellulose, poly(ethylene oxide), polylactic acid, hydroxypropyl methylcellulose, ethylcellulose, a cellulosic polymer, an acrylic polymer, a fat, a wax, a lipid, a polysaccharide, or mixture thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/822,568 US20150343113A1 (en) | 2007-02-08 | 2015-08-10 | Polymeric sealant for use in mammals (as amended) |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/704,115 US8088095B2 (en) | 2007-02-08 | 2007-02-08 | Polymeric sealant for medical use |
US13/323,636 US9119896B2 (en) | 2007-02-08 | 2011-12-12 | Polymeric sealant for medical use |
US14/822,568 US20150343113A1 (en) | 2007-02-08 | 2015-08-10 | Polymeric sealant for use in mammals (as amended) |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/323,636 Division US9119896B2 (en) | 2007-02-08 | 2011-12-12 | Polymeric sealant for medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150343113A1 true US20150343113A1 (en) | 2015-12-03 |
Family
ID=39686479
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/704,115 Active 2028-09-13 US8088095B2 (en) | 2007-02-08 | 2007-02-08 | Polymeric sealant for medical use |
US13/323,636 Active US9119896B2 (en) | 2007-02-08 | 2011-12-12 | Polymeric sealant for medical use |
US14/822,568 Abandoned US20150343113A1 (en) | 2007-02-08 | 2015-08-10 | Polymeric sealant for use in mammals (as amended) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/704,115 Active 2028-09-13 US8088095B2 (en) | 2007-02-08 | 2007-02-08 | Polymeric sealant for medical use |
US13/323,636 Active US9119896B2 (en) | 2007-02-08 | 2011-12-12 | Polymeric sealant for medical use |
Country Status (2)
Country | Link |
---|---|
US (3) | US8088095B2 (en) |
CN (1) | CN101626762B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552967B (en) | 2006-12-15 | 2015-08-12 | 生命连结有限公司 | Gelatin-transglutaminase hemostatic dressings and encapsulant |
US8932560B2 (en) | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
BRPI0821424A2 (en) * | 2007-12-31 | 2019-09-24 | Acclarent Inc | mucosal tissue dressing and method of use |
CN104031393B (en) | 2008-06-18 | 2017-08-01 | 生命连结有限公司 | Improved cross-linked composition |
US9271706B2 (en) * | 2008-08-12 | 2016-03-01 | Covidien Lp | Medical device for wound closure and method of use |
CA2777467A1 (en) * | 2009-04-27 | 2010-11-04 | Intersect Ent, Inc. | Devices and methods for treating pain associated with tonsillectomies |
WO2011060390A2 (en) | 2009-11-13 | 2011-05-19 | University Of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
WO2011077388A1 (en) | 2009-12-22 | 2011-06-30 | Lifebond Ltd | Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices |
EP2600910B1 (en) | 2010-08-05 | 2016-01-20 | Lifebond Ltd | Dry composition wound dressings and adhesives |
JP5937094B2 (en) | 2010-10-27 | 2016-06-22 | メドトロニック,インコーポレイテッド | Population scab used for airway |
US10016454B2 (en) * | 2012-12-04 | 2018-07-10 | Cohera Medical, Inc. | Silane-containing moisture-curable tissue sealant |
US9616088B2 (en) | 2013-03-13 | 2017-04-11 | Gel-E, Inc. | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
BR112016000381A8 (en) * | 2013-08-12 | 2020-01-07 | Novartis Ag | use of one or more antibiotic compounds to treat optical infections and device for use as a kit |
US10183256B2 (en) * | 2014-06-04 | 2019-01-22 | Yale University | In situ repairing technique for compromised polymeric membranes |
CN105434346A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Preparation composition and preparation method and use thereof |
CN105435227A (en) * | 2014-08-08 | 2016-03-30 | 深圳君圣泰生物技术有限公司 | Liquid preparation composition and preparation method and use and solid preparation thereof |
CN105362220A (en) * | 2014-08-08 | 2016-03-02 | 深圳君圣泰生物技术有限公司 | Preparation, preparation method and uses thereof |
KR102038560B1 (en) * | 2017-07-19 | 2019-11-01 | 순천향대학교 산학협력단 | A preparation method of an porous hemostatic agent using wood based-oxidized cellulose and silk fibroin |
CN113304307B (en) * | 2021-05-21 | 2022-03-25 | 浙江大学 | Polyphosphazene-based hydrogel wound dressing with antibacterial and wet surface adhesion properties and preparation method thereof |
CN114685753B (en) * | 2022-04-27 | 2024-01-02 | 广东粤港澳大湾区黄埔材料研究院 | Tissue regeneration promoting type bi-component medical adhesive as well as preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020106409A1 (en) * | 2001-02-02 | 2002-08-08 | Sawhney Amarpreet S. | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
US20040052850A1 (en) * | 2002-09-13 | 2004-03-18 | Kemal Schankereli | Proteinaceous hemostatic tissue sealant |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB983130A (en) * | 1962-08-06 | 1965-02-10 | Mundipharma Ag | Improvements in preparations for the removal of wax from the ear |
US4002775A (en) * | 1973-07-09 | 1977-01-11 | Kabara Jon J | Fatty acids and derivatives of antimicrobial agents |
JPS527428Y2 (en) | 1973-08-17 | 1977-02-16 | ||
CA1052273A (en) * | 1975-12-18 | 1979-04-10 | Edwin B. Michaels | Antimicrobial compositions |
SU1128917A1 (en) | 1980-12-24 | 1984-12-15 | Кишиневский государственный медицинский институт | Method of treatment of paradontosis |
US4323551A (en) * | 1981-02-19 | 1982-04-06 | The Procter & Gamble Company | Mouthwash compositions |
ATE20824T1 (en) | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING. |
US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
DE3175003D1 (en) | 1981-06-25 | 1986-08-28 | Serapharm Gmbh & Co Kg | Enriched plasma derivative for promoting wound sealing and wound healing |
US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
US4662829A (en) | 1984-01-05 | 1987-05-05 | C. R. Bard, Inc. | Pulsatile pump |
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US5208257A (en) * | 1986-04-21 | 1993-05-04 | Kabara Jon J | Topical antimicrobial pharmaceutical compositions and methods |
CA1302280C (en) | 1986-04-21 | 1992-06-02 | Jon Joseph Kabara | Topical antimicrobial pharmaceutical compositions and methods |
US5017229A (en) * | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US5290552A (en) * | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
IT1219587B (en) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
US4902281A (en) * | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
SU1699430A1 (en) | 1989-03-03 | 1991-12-23 | Кишиневский государственный медицинский институт | Method for treating paradontosis |
CA2019719A1 (en) * | 1990-06-25 | 1991-12-25 | William J. Thompson | Mouthwash |
EP0466397A3 (en) * | 1990-07-10 | 1992-05-06 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo | Treatment of inflammatory diseases with polyoxyethylenesorbitan mono-higher-fatty acid esters |
GB9105995D0 (en) | 1991-03-21 | 1991-05-08 | Smith & Nephew | Wound dressing |
BR9205879A (en) * | 1991-04-10 | 1994-07-05 | Christopher C Capelli | Antimicrobial composition, adhesive composition, mammalian infection treatment process and process for providing antimicrobial protection to a patient |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5229103A (en) * | 1992-04-30 | 1993-07-20 | Hydrodent Laboratories, Inc. | Antiplaque mouthwash concentrate |
IT1260154B (en) * | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN) |
GB9218834D0 (en) | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
CN1091315A (en) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and using method thereof |
US5336163A (en) * | 1993-01-06 | 1994-08-09 | Smith & Nephew Richards, Inc. | Expandable nasal stent |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
DK0797988T3 (en) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
US5480658A (en) * | 1993-07-23 | 1996-01-02 | Melman; Steven A. | Ear and skin cleanser |
US5388574A (en) * | 1993-07-29 | 1995-02-14 | Ingebrethsen; Bradley J. | Aerosol delivery article |
FR2710529A1 (en) | 1993-09-29 | 1995-04-07 | Zirinis Phedon | Aqueous gel for nasal use, pellets, and process for preparing them |
US6544761B2 (en) * | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US6086921A (en) * | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
US5817303A (en) * | 1995-05-05 | 1998-10-06 | Protein Polymer Technologies, Inc. | Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
HU226962B1 (en) * | 1995-08-29 | 2010-03-29 | Fidia Advanced Biopolymers Srl | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives |
US5601594A (en) * | 1995-09-14 | 1997-02-11 | Best; Barry D. | Nasal stent |
FI955389A0 (en) | 1995-11-09 | 1995-11-09 | Antti Sakari Aaltonen | Prophylactic prophylactic preparations and administration of breast cancer pathogens |
US6423694B1 (en) * | 1996-02-21 | 2002-07-23 | Inspire Pharmaceuticals, Inc. | Method of treating otitis media with uridine triphosphates and related compounds |
AU2676397A (en) | 1996-04-18 | 1997-11-07 | University Technology Corporation | Methods for treating middle and inner ear disorders |
US5693065A (en) | 1996-06-25 | 1997-12-02 | Rains, Iii; B. Manrin | Frontal sinus stent |
US6541460B2 (en) * | 1996-08-07 | 2003-04-01 | George D. Petito | Method for use of hyaluronic acid in wound management |
US5910420A (en) * | 1996-08-16 | 1999-06-08 | Orion-Yhtyma Oy Orion Diagnostica | Method and test kit for pretreatment of object surfaces |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6203822B1 (en) * | 1996-09-03 | 2001-03-20 | University Of Iowa Research Foundation | Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection |
CO4910145A1 (en) | 1996-10-01 | 2000-04-24 | Smithkline Beecham Corp | USE |
KR20000048812A (en) | 1996-10-01 | 2000-07-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Use of Mupirocin for the Manufacture of a Medicament for the Treatment of Bacterial Infections Associated with Colonisation of the Nasopharynx by Pathogenic Organisms |
IT1287967B1 (en) * | 1996-10-17 | 1998-09-10 | Fidia Spa In Amministrazione S | PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE |
ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5709546A (en) * | 1996-11-27 | 1998-01-20 | Waggoner; Mark B. | Water sanitizing system and process |
FR2756739B1 (en) * | 1996-12-05 | 2000-04-28 | Astra Ab | NEW BUDESONIDE FORMULATION |
JP2001527388A (en) * | 1997-01-24 | 2001-12-25 | シュバイツ ゼールム− ウント インフインスティテュト ベルン | A new method for isolating polysaccharides |
US6869938B1 (en) * | 1997-06-17 | 2005-03-22 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
US5925334A (en) * | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
AU751182B2 (en) * | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
US5895781A (en) * | 1997-12-22 | 1999-04-20 | S. C. Johnson & Son, Inc. | Cleaning compositions for ceramic and porcelain surfaces and related methods |
ES2191355T3 (en) * | 1997-12-24 | 2003-09-01 | Britannia Pharmaceuticals Ltd | USE OF A TENSIOACTIVE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF MIDDLE EAR DISORDERS. |
US6541116B2 (en) * | 1998-01-30 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device |
IL123143A (en) * | 1998-02-02 | 2001-08-26 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing mupirocin |
US6623521B2 (en) | 1998-02-17 | 2003-09-23 | Md3, Inc. | Expandable stent with sliding and locking radial elements |
RU2125432C1 (en) | 1998-03-03 | 1999-01-27 | Главный военный клинический госпиталь им.акад.Н.Н.Бурденко | First-aid kit |
US7691829B2 (en) * | 1998-03-24 | 2010-04-06 | Petito George D | Composition and method for healing tissues |
JP3578627B2 (en) * | 1998-05-15 | 2004-10-20 | 株式会社ホギメディカル | Tissue sealant that promotes wound healing |
US6824793B1 (en) | 1998-06-01 | 2004-11-30 | Chiron Corporation | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
US20030079758A1 (en) * | 1998-06-03 | 2003-05-01 | Siegel Phyllis B. | Process and composition for removing biofilm |
US20020022588A1 (en) * | 1998-06-23 | 2002-02-21 | James Wilkie | Methods and compositions for sealing tissue leaks |
US6706290B1 (en) * | 1998-07-06 | 2004-03-16 | Olvai E. Kajander | Methods for eradication of nanobacteria |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
JP2002529545A (en) * | 1998-11-06 | 2002-09-10 | ユニベルシテ ドゥ モントリオール | Improved germicidal and non-sterile solutions for removing biofilms |
US8197461B1 (en) * | 1998-12-04 | 2012-06-12 | Durect Corporation | Controlled release system for delivering therapeutic agents into the inner ear |
WO2000056283A1 (en) | 1999-03-24 | 2000-09-28 | The B.F.Goodrich Company | Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
US6375635B1 (en) | 1999-05-18 | 2002-04-23 | Hydrocision, Inc. | Fluid jet surgical instruments |
US6375963B1 (en) * | 1999-06-16 | 2002-04-23 | Michael A. Repka | Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof |
US20020061281A1 (en) | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
CA2385150C (en) * | 1999-09-15 | 2010-11-23 | Cryolife, Inc. | Vascular coating composition |
US6533749B1 (en) * | 1999-09-24 | 2003-03-18 | Medtronic Xomed, Inc. | Angled rotary tissue cutting instrument with flexible inner member |
EP1214056B1 (en) * | 1999-09-24 | 2003-10-29 | Alcon Inc. | Topical suspension formulations containing ciprofloxacin and dexamethasone |
US6676930B2 (en) * | 1999-11-28 | 2004-01-13 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
GB0002229D0 (en) * | 2000-02-01 | 2000-03-22 | Reckitt & Colman Inc | Improvements in or relating to organic compositions |
WO2001064035A2 (en) * | 2000-02-28 | 2001-09-07 | The Procter & Gamble Company | Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof |
US20030009213A1 (en) * | 2000-03-13 | 2003-01-09 | Jun Yang | Stent having cover with drug delivery capability |
US6379382B1 (en) * | 2000-03-13 | 2002-04-30 | Jun Yang | Stent having cover with drug delivery capability |
CA2410796C (en) * | 2000-06-05 | 2007-05-01 | S.C. Johnson & Son, Inc. | Biocidal cleaning method |
US20020029015A1 (en) * | 2000-07-04 | 2002-03-07 | Edoardo Camenzind | Device for administering a composition in a duct of a human or animal body |
US6953772B2 (en) | 2000-07-18 | 2005-10-11 | Lopes John A | Concentrated sanitizing compositions for cleaning food and food contact surfaces |
AUPQ893200A0 (en) * | 2000-07-21 | 2000-08-17 | Whiteley, Reginald K. | Medical residue treatment |
US20030133883A1 (en) * | 2001-06-14 | 2003-07-17 | Finnegan Mary Beth | Oral care compositions containing grapefruit seed extract |
GB0100761D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
US6623513B2 (en) | 2001-01-19 | 2003-09-23 | Advanced Photodynamic Technologies, Inc. | Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin |
DE10105592A1 (en) * | 2001-02-06 | 2002-08-08 | Achim Goepferich | Placeholder for drug release in the frontal sinus |
US6610314B2 (en) * | 2001-03-12 | 2003-08-26 | Kimberly-Clark Worldwide, Inc. | Antimicrobial formulations |
US6682695B2 (en) | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
US6962813B2 (en) | 2001-05-21 | 2005-11-08 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
CA2459471C (en) * | 2001-09-13 | 2010-02-02 | Jerry W. Schoen | Method of continuously casting electrical steel strip with controlled spray cooling |
ES2250739T3 (en) * | 2001-09-21 | 2006-04-16 | Alcon, Inc. | METHOD FOR TREATING MID EAR INFECTIONS. |
US20030064000A1 (en) | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
AU2003205227A1 (en) | 2002-01-18 | 2003-09-02 | Emory University | Phthalocyanine and porphyrazine pharmaceutical compositions |
US20050042240A1 (en) * | 2002-01-28 | 2005-02-24 | Utterberg David S. | High viscosity antibacterials |
US20030180181A1 (en) | 2002-02-01 | 2003-09-25 | Teri Greib | Methods for sterilizing tissue |
RU2228203C2 (en) | 2002-04-12 | 2004-05-10 | ООО "Наука-Сервис-Центр" | Wound-healing material |
EP1499341A4 (en) | 2002-04-18 | 2010-10-27 | Univ Iowa Res Found | Methods of inhibiting and treating bacterial biofilms by metal chelators |
US6919348B2 (en) * | 2002-05-02 | 2005-07-19 | Edward T. Wei | Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith |
EP1374856A1 (en) | 2002-06-18 | 2004-01-02 | Impetus AG | Oily thixotropic nasal spray |
US7105175B2 (en) | 2002-06-19 | 2006-09-12 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
US7378479B2 (en) | 2002-09-13 | 2008-05-27 | Lubrizol Advanced Materials, Inc. | Multi-purpose polymers, methods and compositions |
AU2003272517A1 (en) | 2002-09-13 | 2004-04-30 | Zicam, Llc. | Compositions to reduce congestion and methods for application thereof to the nasal membrane |
US20050064508A1 (en) * | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
WO2004026267A2 (en) | 2002-09-23 | 2004-04-01 | Genta Inc. | Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them |
US6770729B2 (en) * | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
KR20050074464A (en) | 2002-09-30 | 2005-07-18 | 보오슈 앤드 롬 인코포레이팃드 | Bacterial attachment reduction to biomaterials and biomedical devices |
AU2003286575A1 (en) * | 2002-10-22 | 2004-05-13 | Nucryst Pharmaceuticals Corp. | Prophylactic treatment methods |
US20040101506A1 (en) * | 2002-11-25 | 2004-05-27 | Fust Charles A. | Composition for the prevention and treatment of inflammation of the ear |
US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
US7491234B2 (en) * | 2002-12-03 | 2009-02-17 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents |
GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
JP2006520786A (en) * | 2003-03-14 | 2006-09-14 | シネクサス, インコーポレイテッド | Sinus delivery of sustained-release therapeutic agents |
US20040214753A1 (en) | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
DE602004025217D1 (en) * | 2003-04-04 | 2010-03-11 | Tissuemed Ltd | |
US20040213758A1 (en) | 2003-04-23 | 2004-10-28 | Rimon Therapeutics Ltd. | Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases |
US7090882B2 (en) * | 2003-06-12 | 2006-08-15 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
US7341983B2 (en) * | 2003-08-04 | 2008-03-11 | Ecolab Inc. | Antimicrobial compositions including carboxylic acids and alkoxylated amines |
JP2007502823A (en) | 2003-08-15 | 2007-02-15 | キューエルティー・ユーエスエイ・インコーポレーテッド | Adhesive and bioerodible transmucosal drug delivery systems |
US20050080396A1 (en) * | 2003-10-03 | 2005-04-14 | Michael Rontal | Method and apparatus for the ultrasonic cleaning of biofilm coated surfaces |
DE10347994A1 (en) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Aqueous aerosol preparation |
WO2005055723A1 (en) * | 2003-12-04 | 2005-06-23 | The University Of Iowa Research Foundation | Gallium inhibits biofilm formation |
ZA200605583B (en) | 2003-12-17 | 2009-06-24 | Titan Pharmaceuticals Inc | Use of gallium to treat inflammatory arthritis |
US20060003008A1 (en) * | 2003-12-30 | 2006-01-05 | Gibson John W | Polymeric devices for controlled release of active agents |
WO2005089670A1 (en) | 2004-03-15 | 2005-09-29 | Durect Corporation | Pharmaceutical compositions for administration to a sinus |
EP1737378A2 (en) * | 2004-04-02 | 2007-01-03 | Baylor College of Medicine | Novel modification of medical prostheses |
US7803150B2 (en) | 2004-04-21 | 2010-09-28 | Acclarent, Inc. | Devices, systems and methods useable for treating sinusitis |
US7410480B2 (en) * | 2004-04-21 | 2008-08-12 | Acclarent, Inc. | Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders |
US20050282722A1 (en) | 2004-06-16 | 2005-12-22 | Mcreynolds Kent B | Two part cleaning composition |
US7494963B2 (en) * | 2004-08-11 | 2009-02-24 | Delaval Holding Ab | Non-chlorinated concentrated all-in-one acid detergent and method for using the same |
US20060045850A1 (en) * | 2004-08-30 | 2006-03-02 | Qpharma, Llc | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids |
US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
CN101040052A (en) | 2004-09-10 | 2007-09-19 | 诺维信北美公司 | Methods for preventing, removing, reducing, or disrupting biofilm |
TW200719884A (en) | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
US20100240770A1 (en) | 2005-03-11 | 2010-09-23 | Jifa Qi | Synthesis and use of colloidal III-V nanoparticles |
US20070264226A1 (en) | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
US7976873B2 (en) | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
US20070264296A1 (en) | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7959943B2 (en) | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US7993675B2 (en) | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US7998404B2 (en) | 2006-07-13 | 2011-08-16 | Advanced Cardiovascular Systems, Inc. | Reduced temperature sterilization of stents |
AU2007346705B2 (en) | 2007-02-08 | 2014-01-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use |
-
2007
- 2007-02-08 US US11/704,115 patent/US8088095B2/en active Active
- 2007-05-08 CN CN2007800510515A patent/CN101626762B/en active Active
-
2011
- 2011-12-12 US US13/323,636 patent/US9119896B2/en active Active
-
2015
- 2015-08-10 US US14/822,568 patent/US20150343113A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020106409A1 (en) * | 2001-02-02 | 2002-08-08 | Sawhney Amarpreet S. | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
US20040052850A1 (en) * | 2002-09-13 | 2004-03-18 | Kemal Schankereli | Proteinaceous hemostatic tissue sealant |
Non-Patent Citations (2)
Title |
---|
Anonymous. Sigma-Aldrich Product Specification [online]; downloaded from <URL http://www.signaaldrich.com/Graphics/COfAInfo/SigmaSAPQM/SPEC/76/764582/764582___Aldrich_.pdf > on June 17, 2017; 1 page. * |
Gross et al. The Laryngoscope. 2001; 111: 259-263. * |
Also Published As
Publication number | Publication date |
---|---|
US8088095B2 (en) | 2012-01-03 |
US9119896B2 (en) | 2015-09-01 |
US20080195037A1 (en) | 2008-08-14 |
CN101626762B (en) | 2013-02-27 |
CN101626762A (en) | 2010-01-13 |
US20120184926A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088095B2 (en) | Polymeric sealant for medical use | |
EP2921138B1 (en) | Implant system for treating sinusitis or allergic rhinitis | |
US8535707B2 (en) | Devices and methods for delivering active agents to the osteomeatal complex | |
EP2051695B1 (en) | Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex | |
AU2020257142B2 (en) | Biodegradable, active ingredient-eluting structural support | |
US7959943B2 (en) | Solvating system and sealant for medical use in the middle or inner ear | |
US10159768B2 (en) | Multi-layer biodegradable device having adjustable drug release profile | |
EP2120908B1 (en) | Solvating system and sealant for medical use | |
CN106137482A (en) | A kind of nasal sinuses support and induction system | |
EP3956008A1 (en) | Biodegradable nasal splint | |
US20220054405A1 (en) | Submucosal bioresorbable drug eluting platform | |
CN204766053U (en) | Nasal sinus support and conveying system | |
US20220072798A1 (en) | Systems And Methods For Forming A Customized Therapeutic Support | |
AU2013211488B2 (en) | Solvating system and sealant for medical use | |
CN110141559A (en) | It is a kind of for the pastille slow-release particle of schneiderian membrane and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |